Marijuana has the strongest evidence for relieving chronic pain, reducing seizures in certain forms of epilepsy, easing muscle spasticity in multiple sclerosis, and controlling nausea from chemotherapy. Beyond those well-studied uses, it shows more modest or mixed results for sleep problems, appetite loss, PTSD, and glaucoma. Here’s what the research actually supports, condition by condition.
Chronic Pain
Pain relief is the most common reason people use medical marijuana, and it’s where the largest body of evidence exists. The picture is nuanced, though. Across all pain conditions, cannabinoids typically reduce pain scores by only 4 to 9 points on a 100-point scale. On a standard 0-to-10 pain scale, the average improvement rarely exceeds half a point to one full point. That’s statistically detectable but small enough to raise questions about whether patients truly feel a meaningful difference.
The strongest results come from nerve pain (neuropathic pain), where cannabinoids nearly doubled the chance of a patient achieving at least a 30% reduction in pain. One study of inhaled cannabis containing both THC and CBD found that 67% of patients experienced pain relief within two hours, with effects lasting up to 48 hours. A combination of THC and CBD appears to work better than either compound alone: 90% of patients on the combination achieved meaningful pain reduction compared to 55% without it.
So while the average numbers look modest, a subset of chronic pain patients, particularly those with nerve-related pain, does experience real relief. This is especially relevant for people who haven’t responded well to other treatments.
Epilepsy and Seizure Disorders
This is the area where a cannabis-derived compound has the clearest, most rigorous evidence behind it. The FDA has approved Epidiolex, a purified form of CBD, for treating seizures in patients two years and older with Lennox-Gastaut syndrome or Dravet syndrome, two severe forms of childhood epilepsy that often resist standard medications.
In clinical trials, patients with Lennox-Gastaut syndrome who took CBD experienced a 44% reduction in monthly drop seizures, compared to 22% in the placebo group. For Dravet syndrome, 43% of patients saw their convulsive seizure frequency cut in half or more over a 14-week treatment period. These are meaningful results for families dealing with conditions where seizures can occur dozens of times per day.
Chemotherapy-Related Nausea
Two synthetic cannabinoid medications, dronabinol (sold as Marinol and Syndros) and nabilone (Cesamet), are FDA-approved specifically for nausea and vomiting caused by cancer chemotherapy. They’re recommended when standard anti-nausea drugs haven’t worked. Their effectiveness appears roughly comparable to some conventional options rather than clearly superior.
The American Society of Clinical Oncology guidelines position these cannabinoid drugs as a backup option, not a first-line treatment. And there’s an important distinction: the guidelines note that evidence is still insufficient to recommend smoked or ingested marijuana itself for chemotherapy nausea, even though the pharmaceutical versions have approval.
Multiple Sclerosis and Muscle Spasticity
More than half of people with multiple sclerosis develop spasticity, the painful muscle stiffness and involuntary tightening that worsens over time. By 15 years after diagnosis, roughly three-quarters of patients are affected. A mouth spray containing both THC and CBD (nabiximols) is the most studied cannabinoid treatment for this symptom, and research consistently shows it helps.
A large meta-analysis found that cannabinoid treatment produced a significant improvement on spasticity rating scales, with patients reporting roughly a 40% reduction in spasticity scores. Both patient-reported stiffness and clinician-measured muscle resistance improved after treatment. For people with MS whose spasticity hasn’t responded adequately to other medications, this represents a meaningful option.
Appetite and Weight Loss
Dronabinol is FDA-approved to treat the appetite loss and wasting that can accompany AIDS. In clinical studies, HIV-positive patients using marijuana or dronabinol gained about 3.2 to 3.5 kg over the study period, compared to 1.3 kg for those on placebo. Both smoked marijuana and the oral medication produced comparable increases in food intake.
For cancer-related weight loss, the picture is less encouraging. In a study of 469 patients with advanced cancer, the conventional appetite stimulant megestrol led to significantly more weight gain than dronabinol (11% of baseline body weight versus 3%). So while cannabinoids do stimulate appetite, they aren’t necessarily the most effective option for every wasting condition. There’s also evidence that the appetite boost may diminish with repeated use as tolerance develops.
Sleep
Many people turn to marijuana for sleep, and there is some support for the idea that it helps you fall asleep faster. Across multiple studies using subjective sleep measures, the most consistent finding was a decrease in sleep latency, meaning people reported falling asleep more quickly after using cannabis. One study found that a 15 mg dose of THC shortened the time to fall asleep but also increased next-day sleepiness.
Beyond falling asleep faster, the evidence gets murky. Studies using objective sleep monitoring equipment have produced contradictory results. Some found increases in deep sleep, others found decreases, and some found no change at all. THC does appear to suppress REM sleep, the phase associated with dreaming, though results across studies are inconsistent. This REM suppression is one reason some PTSD patients report fewer nightmares with cannabis use, but it also raises questions about long-term sleep quality since REM sleep plays important roles in memory and emotional processing.
Glaucoma
Marijuana does lower the pressure inside the eye, which is the main risk factor for glaucoma. But the effect lasts only 3 to 4 hours before pressure returns to baseline. Maintaining consistently lower eye pressure would require smoking roughly 8 to 10 times per day, which is impractical and would cause significant side effects. Modern glaucoma treatments, including eye drops and surgical options, provide 24-hour pressure control with far fewer drawbacks. Most ophthalmology organizations do not recommend marijuana as a glaucoma treatment for this reason.
PTSD
PTSD is one of the most common qualifying conditions for medical marijuana programs across the United States, and many patients report improvements in nightmares, hyperarousal, and sleep disruption. The rationale makes biological sense: the body’s own cannabinoid system is involved in fear extinction and stress response. However, the clinical trial data remains limited. Most of the positive evidence comes from observational studies and patient surveys rather than the kind of rigorous controlled trials that exist for epilepsy or spasticity. It’s a promising area, but one where personal reports have outpaced the formal evidence.
Important Considerations
Both CBD and THC interact with the liver enzymes that break down many common medications, particularly a family of enzymes responsible for metabolizing blood thinners, certain antidepressants, and anti-seizure drugs. If you take medications with a narrow margin between an effective dose and a harmful one, adding cannabis could alter how those drugs are processed in your body and change their blood levels. This is especially relevant for people using high-dose CBD products.
The form of cannabis matters. Smoked or vaped cannabis acts within minutes but carries respiratory concerns. Edibles take 30 minutes to two hours to kick in but last longer. Pharmaceutical-grade products like Epidiolex and dronabinol offer standardized dosing, while dispensary products vary widely in potency and composition. The ratio of THC to CBD also shapes the experience: THC is primarily responsible for pain relief, appetite stimulation, and the psychoactive effects, while CBD contributes to seizure control and may temper some of THC’s side effects.
Across all conditions, the side effects most commonly reported with cannabinoid use include dizziness, drowsiness, dry mouth, and cognitive changes. These tend to be dose-dependent and are more pronounced with THC-dominant products. For most of the conditions described above, cannabis works best as an add-on when standard treatments haven’t provided adequate relief, not as a replacement for first-line therapies.